



## (51) International Patent Classification:

A61K 31/5375 (2006.01) A61P 13/02 (2006.01)

## (21) International Application Number:

PCT/US2019/033768

## (22) International Filing Date:

23 May 2019 (23.05.2019)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

|            |                          |    |
|------------|--------------------------|----|
| 62/677,484 | 29 May 2018 (29.05.2018) | US |
| 15/993,267 | 30 May 2018 (30.05.2018) | US |
| 15/993,287 | 30 May 2018 (30.05.2018) | US |

## (71) Applicant: SAREPTA THERAPEUTICS, INC.

[US/US]; 215 First Street, Cambridge, MA 02142 (US).

## (72) Inventors: BESTWICK, Richard, K.; C/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US).

HANSON, Gunnar, J.; C/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US).

PASSINI, Marco, A.; C/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US).

SCHNELL,

Frederick, Joseph; C/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US).

(74) Agent: VERNI, Christopher et al.; Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US).

## (81) Designated States (unless otherwise indicated, for every kind of national protection available):


AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

## (84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

## (54) Title: EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY

Figure 4



(57) Abstract: Antisense oligomers and antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*